Physician profile
Roberta Lockhart
NPI 1811907686
$3,528.96
in general payments reported to CMS, 2019-2025
32 companies · $666 in 2025
The $666 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $386 · 2021: $391 · 2022: $382 · 2023: $608 · 2024: $564 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $553.20 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Sanofi Pasteur INC. | $366.57 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $343.02 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $331.29 | 2019-2025 | Doc Band |
| Pfizer INC. | $303.60 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $265.67 | 2019-2022 | |
| Corium, LLC | $205.72 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $195.86 | 2019-2025 | Bexsero, Rotarix, Penmenvy |
| Kaleo, INC. | $140.38 | 2019-2023 | Auvi-Q |
| Phadia US INC. | $85.47 | 2022-2025 | Immunocap |
| Ironshore Pharmaceuticals INC. | $79.69 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $78.12 | 2024-2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $67.16 | 2019-2024 | Relexxii |
| Verrica Pharmaceuticals INC. | $51.32 | 2023-2024 | Ycanth |
| Cepheid | $40.35 | 2023 | Genexpert |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $38.94 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $35.33 | 2019-2020 | |
| Shire North American Group INC | $34.90 | 2019 | |
| Sobi, INC | $34.59 | 2019-2020 | |
| Alk-Abello, INC | $34.40 | 2023 | Ragwitek, Odactra, Grastek |
| Qol Medical, LLC | $30.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.57 | 2024-2025 | |
| Organon LLC | $23.80 | 2025 | |
| Abbvie INC. | $23.05 | 2021 | |
| Ironwood Pharmaceuticals, INC | $22.97 | 2024 | |
| Aimmune Therapeutics, INC. | $19.14 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $18.33 | 2024 | Zoryve |
| Mission Pharmacal Company | $17.47 | 2019 | |
| Genentech USA, INC. | $16.07 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $15.73 | 2025 | Neffy |
| Neos Therapeutics, Lp | $14.81 | 2019 | |
| Aytu Biopharma, INC. | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Lockhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.